These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 26618550)
21. High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey. Kim SW; Asakura Y; Tajima K; Iwai T; Taji H; Chou T; Morishima Y; Suzumiya J; Sakamaki H; Suzuki R; Fukuda T Int J Hematol; 2020 Feb; 111(2):256-266. PubMed ID: 31732878 [TBL] [Abstract][Full Text] [Related]
22. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004 [TBL] [Abstract][Full Text] [Related]
23. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796 [TBL] [Abstract][Full Text] [Related]
24. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475 [TBL] [Abstract][Full Text] [Related]
25. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Rohlfing S; Dietrich S; Witzens-Harig M; Hegenbart U; Schönland S; Luft T; Ho AD; Dreger P Ann Hematol; 2018 Jul; 97(7):1241-1250. PubMed ID: 29549411 [TBL] [Abstract][Full Text] [Related]
27. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. Eyre TA; Caillard S; Finel H; Boumendil A; Kothari J; Zimmermann H; Trappe RU; De Wilde V; Tholouli E; Kanfer E; Broom A; Damaj G; Bargetzi M; Kozák T; Hilgendorf I; Crawley C; Kerre T; Trněný M; Bachy E; Robinson S; Montoto S Bone Marrow Transplant; 2021 Sep; 56(9):2118-2124. PubMed ID: 33864020 [TBL] [Abstract][Full Text] [Related]
28. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Martino R; Bellido M; Brunet S; Sureda A; Peyret M; Guárdia R; Altés A; Domingo-Albós A; Sierra J Bone Marrow Transplant; 1998 May; 21(10):1023-7. PubMed ID: 9632276 [TBL] [Abstract][Full Text] [Related]
29. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082 [TBL] [Abstract][Full Text] [Related]
30. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
31. Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation? Willemze R; Labar B Semin Hematol; 2007 Oct; 44(4):267-73. PubMed ID: 17961726 [TBL] [Abstract][Full Text] [Related]
32. Management of Relapsed Diffuse Large B-cell Lymphoma. Crump M Hematol Oncol Clin North Am; 2016 Dec; 30(6):1195-1213. PubMed ID: 27888875 [TBL] [Abstract][Full Text] [Related]
33. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. Kyriakou C; Canals C; Finke J; Kobbe G; Harousseau JL; Kolb HJ; Novitzky N; Goldstone AH; Sureda A; Schmitz N J Clin Oncol; 2009 Aug; 27(24):3951-8. PubMed ID: 19620487 [TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. van Kampen RJ; Canals C; Schouten HC; Nagler A; Thomson KJ; Vernant JP; Buzyn A; Boogaerts MA; Luan JJ; Maury S; Milpied NJ; Jouet JP; Ossenkoppele GJ; Sureda A J Clin Oncol; 2011 Apr; 29(10):1342-8. PubMed ID: 21321299 [TBL] [Abstract][Full Text] [Related]
35. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780 [TBL] [Abstract][Full Text] [Related]
36. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563 [TBL] [Abstract][Full Text] [Related]
37. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967 [TBL] [Abstract][Full Text] [Related]
38. Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation. Eyre TA; Barrington SF; Okosun J; Abamba C; Pearce RM; Lee J; Carpenter B; Crawley CR; Bloor AJC; Gilleece M; Nicholson E; Shah N; Orchard K; Malladi R; Townsend WM Haematologica; 2023 Mar; 108(3):785-796. PubMed ID: 35586966 [TBL] [Abstract][Full Text] [Related]
39. Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party. Horstmann K; Boumendil A; Finke J; Finel H; Kanfer E; Milone G; Russell N; Bacigalupo A; Chalandon Y; Diez-Martin JL; Ifrah N; Chacon MJ; Dreger P Bone Marrow Transplant; 2015 Jun; 50(6):790-4. PubMed ID: 25751644 [TBL] [Abstract][Full Text] [Related]
40. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A; Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]